Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Abstract
It is well recognized today that anticancer drugs often are most effective when used in combination. However, the establishment of chemotherapy as key modality in clinical oncology began with sporadic discoveries of chemicals that showed antiproliferative properties and which as a first attempt were used as single agents. In this review we describe the development of chemotherapy from its origins as a single drug treatment with cytotoxic agents to polydrug therapy that includes targeted drugs. We discuss the limitations of the first chemotherapeutic drugs as a motivation for the establishment of combined drug treatment as standard practice in spite of concerns about frequent severe, dose limiting toxicities. Next, we introduce the development of targeted treatment as a concept for advancement within the broader field of small-molecule drug combination therapy in cancer and its accelerating progress that was boosted by recent scientific and technological progresses. Finally, we describe an alternative strategy of drug combinations using drug-conjugates for selective delivery of cytotoxic drugs to tumor cells that potentiates future improvement of drug combinations in cancer treatment. Overall, in this review we outline the development of chemotherapy from a pharmacological perspective, from its early stages to modern concepts of using targeted therapies for combinational treatment.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 07, 2021
- Source ID
- 10.3390/cancers13040669
Entities
People
- Bert W. O’malley
- David M. Lonard
- Gary Gellerman
- Yosi Gilad
Organizations
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- United States Department of Defense